Literature DB >> 2791445

The theophylline-enoxacin interaction: II. Changes in the disposition of theophylline and its metabolites during intermittent administration of enoxacin.

M C Rogge1, W R Solomon, A J Sedman, P G Welling, J R Koup, J G Wagner.   

Abstract

The pharmacokinetics of theophylline and its three major metabolites, 3-methylxanthine, 1-methylurate, and 1,3-dimethylurate, were studied during intermittent administration of enoxacin. The addition of enoxacin (400 mg, twice daily) to a theophylline dosing regimen (150 mg, twice daily) resulted in an immediate fall in plasma theophylline metabolite concentrations. Mean steady-state theophylline concentration in plasma during the dosing interval increased from 3.17 to 8.23 micrograms/ml. The mean 12-hour recovery of total theophylline metabolite decrease from 76.3 to 38.6 mg. After the discontinuation of enoxacin, but not theophylline, the plasma theophylline metabolite levels immediately increased to near or above the concentrations observed before enoxacin coadministration. Concurrently, theophylline concentrations decreased to levels equivalent to those observed before enoxacin coadministration. In general, the changes in plasma theophylline concentrations observed after the addition of discontinuation of enoxacin were complete within 3 days.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2791445     DOI: 10.1038/clpt.1989.160

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  7 in total

Review 1.  Pharmacokinetic interactions between theophylline and other medication (Part II).

Authors:  R A Upton
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

2.  Safety of fleroxacin coadministered with theophylline to young and elderly volunteers.

Authors:  M Parent; M St-Laurent; M LeBel
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

Review 3.  Enoxacin: a reappraisal of its clinical efficacy in the treatment of genitourinary tract infections.

Authors:  S S Patel; C M Spencer
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 4.  Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Focus on biotransformation.

Authors:  U Tröger; F P Meyer
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

5.  Theophylline dosage adjustment during enoxacin coadministration.

Authors:  J R Koup; R D Toothaker; E Posvar; A J Sedman; W A Colburn
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

Review 6.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

Review 7.  Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions.

Authors:  F Pea; M Furlanut
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 5.577

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.